Yong-Mi Kim

Professor of Pediatrics and Pathology

United States

Research Interests

Explore related searches

Professors in United States Professors in Cancer Biology Cancer Biology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Yong-Mi Kim is a Professor of Pediatrics and Pathology at the University of Southern California Keck School of Medicine and Children's Hospital Los Angeles. Her research focuses on acute lymphoblastic leukemia and hematological malignancies, with recent articles exploring Wnt signaling, PI3K targeting, and novel therapeutic strategies. She also investigates the physical phenotypes of leukemia cells post-chemotherapy and the effects of innovative compounds in preclinical models.

Articles (11)

Year:

2025

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (3)

Oliver Bell

Assistant Professor

University of Southern California Keck School of Medicine

UNITED STATES

View details

Axel Schönthal

University of Southern California

UNITED STATES

View details

Tomohiko Ai

JAPAN

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Yong-Mi Kim

Research Interests

Explore related searches

Contact this professor

About

Articles (11)

Targeting Wnt Signaling in Acute Lymphoblastic Leukemia

Altered physical phenotypes of leukemia cells that survive chemotherapy treatment.

Artemis inhibition as a therapeutic strategy for acute lymphoblastic leukemia.

Editorial: New immunotherapeutic and pharmacological targets and strategies in haematological malignancies.

PI3K Targeting in Non-solid Cancer.

Potentially Curative Therapeutic Activity of NEO212, a Perillyl Alcohol-Temozolomide Conjugate, in Preclinical Cytarabine-Resistant Models of Acute Myeloid Leukemia

Preclinical Evaluation of a Novel Dual Targeting PI3Kδ/BRD4 Inhibitor, SF2535, in B-Cell Acute Lymphoblastic Leukemia.

<i>In vitro</i> and <i>in vivo</i> effects of AVA4746, a novel competitive antagonist of the ligand binding of VLA-4, in B-cell acute lymphoblastic leukemia.

Reprogramming CBX8-PRC1 function with a positive allosteric modulator.

Exogenous mitochondrial transfer and endogenous mitochondrial fission facilitate AML resistance to OxPhos inhibition.

Wnt Signaling in the Tumor Microenvironment.

Collaborators (3)

Oliver Bell

Axel Schönthal

Tomohiko Ai

Make your next move.